Category IP-Watch Briefs

Obama 2012 Budget Proposal Reduces Exclusivity For Biologics

Shortly after passage last year of the US healthcare reform act called for a regulatory pathway to bring follow-on biologic drugs, or biosimilars, to market with 12 years of data exclusivity for brand-name producers, the Obama administration has proposed to reduce that time to its original 7 years, according to sources. The move, contained in the 2012 budget proposal, is expected to allow lower priced generic versions of drugs to enter the market sooner, a benefit to consumers.